LMNL News and Press, Liminal Biosciences Inc From 02/15/23

Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement Canada NewsWire LAVAL, QC , Feb. 15, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from...

Liminal BioSciences ( NASDAQ: LMNL ) on Thursday said it would effect a 10-for-1 reverse stock split. LMNL stock fell 2.8% to $0.40 after hours. The reverse stock split will become effective on Feb. 1, LMNL said in a statement. The company's trading symbol will remain unch...

Liminal BioSciences Announces Reverse Stock Split Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Jan. 26, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued an...

Liminal BioSciences to Present at BIO CEO & Investor Conference Liminal BioSciences to Present at BIO CEO & Investor Conference PR Newswire LAVAL, QC and CAMBRIDGE, England , Jan. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL...

Liminal BioSciences Announces Priorities For 2023 Canada NewsWire Closed December 2022 with just over CAD 37 million cash on hand, expecting to provide a runway into early 2024. Plans to divest its remaining non-core assets, to further extend runway. ...

Liminal BioSciences Announces Holding of Special Meeting of Shareholders Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Nov. 25, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it will ...

Liminal Biosciences (LMNL) Q3 2022 Earnings Conference Call November 10, 2022 08:30 ET Company Participants Shrinal Inamdar - Investor Relations Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Chief Financial Officer Presentation Operator ...

The following slide deck was published by Liminal BioSciences Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Liminal BioSciences Inc. 2022 Q3 - Results - Earnings Call Presentation

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights Canada NewsWire $40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement f...

Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022 Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Nov. 8, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company")...